Human Anti-B. Pertussis FHA IgG ELISA Kit

Sample

Serum, plasma or other biological fluids

Species Reactivity

Human

Detection Method

iELISA

Intended Use

The Human Anti-B. Pertussis FHA IgG ELISA Kit detects and quantifies B. pertussis FHA-specific IgG in serum or plasma of vaccinated or immunized humans. This ELISA is suitable for:
1. Determining immune status relative to non-immune controls;
2. Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
3. Qualifying and/or standardizing vaccine batches and protocols.
For research use only (RUO), not for diagnosis, cure or prevention of the disease.

Contents of Kit

1. Wash Solution Concentrate (100×), 10ml.
2. Sample Diluent Concentrate (20×), 10ml.
3. Anti-Human IgG-HRP Conjugate Concentrate (100×), 0.15ml.
4. FHA Coated Strip Plate, 8-well strips (12). Coated with FHA, and post-coated with stabilizers.
5. Anti- FHA Calibrators, 0.65ml. Four (4) vials, each containing anti-FHA; in buffer with antimicrobial. 1 U/ml, 2.5 U/ml, 5 U/ml, 10 U/ml.
6. Human Anti-FHA IgG Positive Control. 0.65ml. Human anti-FHA; diluted in buffer with protein, detergents and antimicrobial. Net OD > 0.5.
7. Low NSB Sample Diluent. Reduces non-specific binding. 30 ml. Buffer with protein, detergents and antimicrobial. Use as is for sample dilution.
8. TMB Substrate. 12 ml. Chromogenic substrate for HRP containing TMB and peroxide.
9. Stop Solution. 12 ml. Dilute sulfuric acid.

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.

Sensitivity

The FHA coating level, HRP conjugate concentration and Low NSB Sample Diluent are optimized to differentiate anti-FHA IgG from background (non-antibody) signal with human serum samples diluted 1:100.

General Description

Pertussis, also known as Whooping Cough, is a highly contagious disease caused by Bordetella pertussis bacteria. Vaccines for pertussis, available in combination with vaccines for tetanus, diphtheria, H. influenza B, hepatitis & polio, use acellular components, primarily the inactivated pertussis toxin. The toxin, a protein exotoxin, produced only by B. pertussis, is central to pertussis pathogenesis; vaccination with the toxoid elicits high levels of protection from the disease. Also included are two other highly immunogenic pertussis proteins: pertactin and filamentous hemagglutinin (FHA). It is one of two hemagglutinins produced by phase I strains of B. pertussis. FHA is a protein with ~ 200 Kda. which binds to sulfatides that are found on cilia of epithelial cells. Once anchored, the bacterium produces tracheal cytotoxin, which stops the cilia from beating. This prevents the cilia from clearing debris from the lungs, so the body responds by sending the host into a coughing fit. These coughs expel some bacteria into the air, which are free to infect other hosts.
The Anti-B. Pertussis FHA IgG ELISAs will quantify antibodies produced by vaccines as well as from infection with the toxin-producing organisms.